Designation of Recombinant Human Coagulation Factor VIII FC Fusion Protein as an Orphan Drug - Biogen Idec Australia Pty Ltd

Overview

The Designation of Recombinant Human Coagulation Factor VIII Fc Fusion Protein as an Orphan Drug was gazetted under the authority of C2013G00364 in 2013. This legislative instrument was enacted to address the need for incentivising the development of treatments for rare diseases by providing certain benefits to drugs intended for conditions affecting a small population. The objective of this designation, as outlined in the Therapeutic Goods Regulations 1990, is to facilitate the availability of orphan drugs that meet unmet medical needs, particularly for serious or life-threatening conditions where there is no satisfactory method of diagnosis, prevention, or treatment. By designating recombinant human coagulation factor VIII Fc fusion protein as an orphan drug, the Australian government aims to encourage the research and development of innovative treatments for haemophilia A, a rare blood disorder.

Scope and Application

This legislation pertains to the designation of recombinant human coagulation factor VIII Fc fusion protein as an orphan drug, applicable for the treatment and prevention of bleeding episodes in both adults and children suffering from haemophilia A. The legislation identifies Dr Anthony Gill, Delegate of the Secretary, as the authority responsible for this designation under subregulation 16J (2) of the Therapeutic Goods Regulations 1990. The scope of the legislation extends to the specific drug in its designated form, which is lyophilized powder for reconstitution via intravenous injection. The sponsor of the drug is Biogen Idec Australia Pty Ltd. This designation is geographically applicable within the jurisdiction governed by the Therapeutic Goods Regulations 1990, implying a Commonwealth reach. There are no stated exclusions, exemptions, or thresholds in this specific piece of legislation. The application of this Act may be further extended or restricted through subordinate instruments, though such details are not provided within the scope of this particular designation.

Key Provisions

The key operative sections of the designation notice establish the criteria and process for recognising a specific therapeutic product as an orphan drug under the Therapeutic Goods Regulations 1990 (Regulations). Section 16J(2) of the Regulations allows for the designation of a drug as an orphan drug if it is intended for the treatment, prevention or diagnosis of a rare disease or condition. In this instance, recombinant human coagulation factor VIII Fc fusion protein has been designated as an orphan drug for the treatment and prevention of bleeding episodes in patients with haemophilia A, as stated in section 16J(2). This designation was made on 22 February 2013 by Dr Anthony Gill, Delegate of the Secretary, and is applicable to the specific dosage form of the drug, which is a lyophilized powder for reconstitution and intravenous injection (section 16J(2)). The sponsor of this drug, Biogen Idec Australia Pty Ltd, is identified as the entity responsible for the drug’s development and distribution (section 16J(2)). The designation of recombinant human coagulation factor VIII Fc fusion protein as an orphan drug imposes several obligations and requirements on the parties involved. Firstly, the sponsor, Biogen Idec Australia Pty Ltd, must ensure that the drug meets the regulatory standards for safety, efficacy, and quality as outlined in the Regulations (section 16J(2)). The sponsor is also responsible for conducting and submitting necessary clinical trials and other research data to support the orphan drug designation (section 16J(2)). Additionally, the sponsor must provide ongoing updates to the Therapeutic Goods Administration (TGA) regarding the drug’s development, manufacturing, and distribution (section 16J(2)). The TGA, in turn, is responsible for monitoring compliance with the Regulations and ensuring that the orphan drug designation is appropriate and continues to meet the criteria for orphan status (section 16J(2)). Failure to comply with the obligations and requirements set forth in the Regulations can result in various civil, criminal, and administrative consequences. Firstly, if the sponsor does not meet the standards for safety, efficacy, and quality, the TGA can take enforcement action, including refusing to approve the drug, imposing fines, or requiring the sponsor to recall the product (section 16J(2)). Additionally, if the sponsor fails to provide necessary updates or information to the TGA, this could lead to administrative penalties, such as additional fines or even revocation of the orphan drug designation (section 16J(2)). Furthermore, if the sponsor engages in fraudulent or misleading practices in the marketing or distribution of the drug, they may face criminal charges, including fines or imprisonment (section 16J(2)). The maximum penalties for these offences are determined by the specific provisions of the Therapeutic Goods Act 1989 and the Regulations, which can include substantial fines and/or imprisonment terms depending on the severity of the breach.